Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Price Performance

CLLS opened at $1.71 on Friday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $1.91 and its 200 day moving average price is $2.08. Cellectis has a fifty-two week low of $1.69 and a fifty-two week high of $3.77. The firm has a market cap of $94.77 million, a price-to-earnings ratio of -1.31 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same period last year, the business posted ($0.31) EPS. As a group, sell-side analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

Several hedge funds have recently added to or reduced their stakes in CLLS. Principal Financial Group Inc. grew its stake in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares in the last quarter. XTX Topco Ltd bought a new position in Cellectis in the 2nd quarter valued at about $29,000. Long Focus Capital Management LLC increased its stake in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. Finally, First Affirmative Financial Network bought a new stake in shares of Cellectis during the 3rd quarter worth about $45,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.